BioPharma Dive’s Post

More people die from the consequences of obesity than from hunger, according to the World Health Organization (WHO). Unsurprisingly, #obesity drugs are becoming increasingly popular: they reduce the risk of diabetes, stroke and high blood pressure. What does this development mean for investors? LGT Equity Analyst Tilman Dumrese observes: "Obesity drugs are and will continue to be a highlight of the pharma sector, but this will not stop the development of treatments for other classic common diseases. While following the obesity saga makes sense for investors, it would be a mistake to overlook promising developments in other, perhaps less starry areas of pharma research and development." More insights and analyses in our article. #investinhealth

A new update to STAT's Obesity Drug Tracker includes features that allow drugs to be filtered by characteristics like development phase, mechanism, and route of administration. Learn more here: https://trib.al/s4Ra4vX

Ozempic Maker Charges $1,000, But Study Says It Can Be Made for Less Than $5 Ozempic could be profitably produced for less than $5 a month even as maker Novo Nordisk A/S charges almost $1,000 in the US, according to a study that revives questions about prices for top-selling treatments for diabetes and obesity. https://lnkd.in/gbXtGbDS

🔦 The recent success of GLP-1 receptor agonists drugs in achieving weight loss has put obesity into the spotlight as a chronic disease that requires comprehensive management. Despite initial positive outcomes, the long-term benefits of these obesity treatments are still under scrutiny. 🔎 In our latest white paper, we dive into some of the open questions related to new obesity treatments, and discuss future opportunities for drug developers to provide more targeted and effective treatments for patients by - 🎯 developing evidence-based guidelines for the physical activity that accompanies pharmaceutical treatments 🎯 capturing low-burden and objective assessments of physical function and sleep quality that are often negatively impacted by obesity Read more here 📒 https://hubs.la/Q02G3Nm_0 #Obesity #PhysicalActivity #Sleep #DrugDevelopment

Thoughts on this? >> With GIP, obesity research is at odds >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #productmarketing #healthcare #pharma

If you're interested in finding out more about the drug pipeline for obesity (and related conditions) this article is a good read. GLP-1 products have been red hot, but there are other mechanisms of action in development, too. A couple things to think about for anyone considering these products. - For GLP-1's (and likely some others) be prepared to lose muscle as well as fat when taking them. - What's your game plan if/when you stop taking the drug? https://lnkd.in/ggWQnSis

Choosing Between Ozempic and Other Weight Loss Drugs Patients now have a choice among drugs like Wegovy, Ozempic, Zepbound, and Mounjaro for obesity treatment. - Semaglutide, sold as Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro, are the primary options. - A recent study showed people lost more weight on Mounjaro compared to Ozempic. - Despite the promising results, experts caution that the studies are highly flawed. - Deciding on the best option remains complicated due to limitations in current research. 👍 https://lnkd.in/dNDMTTf3

"Revolutionizing Obesity Treatment: New Drugs Transforming the Landscape" The future of obesity treatment is undergoing a revolutionary shift with the introduction of innovative drugs. Despite persistent efforts to address obesity through various means, the health and economic impact of this chronic disease continues to escalate, affecting around 800 million people globally. The recent approval of GLP-1s and GLP1/GIPs for obesity has delivered remarkable clinical outcomes, boasting weight loss rates of up to 25%, a significant leap from the 7% achieved by earlier drug classes. This transformative development is reshaping the treatment landscape, offering a credible pathway to overcome obesity through a combination of drugs, technology, coaching, and more. News Daily, a dynamic series delivering bite-sized updates on the ever-evolving Pharma and Lifesciences Industry. Stay at the forefront of #HealthcareInnovation, #BiotechBreakthroughs, and industry insights. Join us on this informative journey - Follow RESONACLE for your daily dose of impactful news and stay ahead in the world of #PharmaNews and #LifesciencesUpdates! #NewsDaily #TrendingInHealthcare #StayInformed #ObesityRevolution #NewDrugsInPharma #HealthTransformation #GLP1GIPBreakthrough #WeightLossInnovation #ChronicDisease #MedicalAdvancements #HealthcareRevolution #ObesityTreatment #ClinicalBreakthroughs

Accelerated obesity drug development, combined with significant unmet need, has set the stage for unprecedented market growth. With a potential market value of up to $131 billion by 2028, the obesity landscape offers a mix of significant opportunity and challenge. Explore the shifting tailwinds and headwinds in our on-demand webinar to stay ahead of this evolving market. #ObesityMarket #IQVIAMIDAS #OnDemandWebinar https://bit.ly/4a8KWrT

How to Plan for the Obesity Drug Revolution Many of your clients who are now struggling with their weight could soon be thin, thanks to the new “glucagon-like peptide-1 agonist” drugs and other weight-loss drugs that show up in the future. The new drugs, Wegovy and Saxenda, have stunned weight-loss experts who once argued that willpower was the only sensible defense against obesity by helping people lose a substantial amount of their weight without much extra effort. Novo Nordisk says weekly use of the drug cuts the risk of heart attack and stroke by about 20%. Read the rest of the article here https://buff.ly/48GEYg2 👈 Visit our website https://buff.ly/3RB8X3L 😄 Watch The Impact of Preventable Disease on Enterprises. https://buff.ly/43DgkdQ 👈 Pre-register here: https://buff.ly/3NzDfAZ 👈 Follow Us on LinkedIn https://buff.ly/48mdZah 👈 #ImmuneSystem #GutMicrobiota #Thier #HealthisWealth #ImmuneHealth #StayHealthy #GutHealthBenefits #FemTech #MaleTech, #WomensHealth, #Innovation #Health #AL #PersonlisedHealth #Technology #Healthcare #Strategy